Tags

Type your tag names separated by a space and hit enter

Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease.
J Clin Neurosci. 2012 Mar; 19(3):343-8.JC

Abstract

Levodopa-induced dyskinesias (LID) represent a substantial barrier to effective symptomatic management of Parkinson's disease, but current treatment options for this debilitating side effect are limited, despite an increasing understanding of their pathophysiology from animal models. Increasing evidence suggests that serotonin neurons have a pivotal role in the induction and maintenance of dyskinesias, and provide a promising target for anti-dyskinetic therapies. Here, we review the evidence for serotonergic involvement in dyskinesias from animal and human data, and highlight some of the translational gaps which may explain why the success of serotonin autoreceptor agonists as anti-dyskinetic agents in experimental models has failed to be replicated in clinical trials.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Cheshire PA
Van Cleef Roet Centre for Nervous Diseases, 4th Floor, Monash University, Alfred Hospital, 89 Commercial Road, Melbourne, Victoria 3004, Australia. Perdita.Cheshire@monash.edu
Williams DR
No affiliation info available

MeSH

AnimalsAnti-Dyskinesia AgentsAntiparkinson AgentsDopamineDopamine AgentsDyskinesia, Drug-InducedHumansLevodopaNeuronsParkinson DiseaseSerotonin

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

22249009

Citation

Cheshire, Perdita A., and David R. Williams. "Serotonergic Involvement in Levodopa-induced Dyskinesias in Parkinson's Disease." Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia, vol. 19, no. 3, 2012, pp. 343-8.
Cheshire PA, Williams DR. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. J Clin Neurosci. 2012;19(3):343-8.
Cheshire, P. A., & Williams, D. R. (2012). Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia, 19(3), 343-8. https://doi.org/10.1016/j.jocn.2011.09.008
Cheshire PA, Williams DR. Serotonergic Involvement in Levodopa-induced Dyskinesias in Parkinson's Disease. J Clin Neurosci. 2012;19(3):343-8. PubMed PMID: 22249009.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. AU - Cheshire,Perdita A, AU - Williams,David R, Y1 - 2012/01/16/ PY - 2011/07/20/received PY - 2011/08/29/revised PY - 2011/09/29/accepted PY - 2012/1/18/entrez PY - 2012/1/18/pubmed PY - 2012/6/1/medline SP - 343 EP - 8 JF - Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia JO - J Clin Neurosci VL - 19 IS - 3 N2 - Levodopa-induced dyskinesias (LID) represent a substantial barrier to effective symptomatic management of Parkinson's disease, but current treatment options for this debilitating side effect are limited, despite an increasing understanding of their pathophysiology from animal models. Increasing evidence suggests that serotonin neurons have a pivotal role in the induction and maintenance of dyskinesias, and provide a promising target for anti-dyskinetic therapies. Here, we review the evidence for serotonergic involvement in dyskinesias from animal and human data, and highlight some of the translational gaps which may explain why the success of serotonin autoreceptor agonists as anti-dyskinetic agents in experimental models has failed to be replicated in clinical trials. SN - 1532-2653 UR - https://www.unboundmedicine.com/medline/citation/22249009/Serotonergic_involvement_in_levodopa_induced_dyskinesias_in_Parkinson's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0967-5868(11)00565-0 DB - PRIME DP - Unbound Medicine ER -